ImmunoGen Probability of Future Stock Price Finishing Under 18.2
| IMGNDelisted Stock | USD 18.20 0.81 4.26% |
ImmunoGen |
ImmunoGen Target Price Odds to finish below 18.2
The tendency of ImmunoGen Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move below current price in 90 days |
| 18.20 | 90 days | 18.20 | about 75.86 |
Based on a normal probability distribution, the odds of ImmunoGen to move below current price in 90 days from now is about 75.86 (This ImmunoGen probability density function shows the probability of ImmunoGen Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days ImmunoGen has a beta of -5.08. This usually indicates as returns on its benchmark rise, returns on holding ImmunoGen are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, ImmunoGen is expected to outperform its benchmark. In addition to that ImmunoGen has an alpha of 3.6233, implying that it can generate a 3.62 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). ImmunoGen Price Density |
| Price |
Predictive Modules for ImmunoGen
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ImmunoGen. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ImmunoGen Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ImmunoGen is not an exception. The market had few large corrections towards the ImmunoGen's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ImmunoGen, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ImmunoGen within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 3.62 | |
β | Beta against Dow Jones | -5.08 | |
σ | Overall volatility | 4.93 | |
Ir | Information ratio | 0.17 |
ImmunoGen Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ImmunoGen for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ImmunoGen can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ImmunoGen is not yet fully synchronised with the market data | |
| ImmunoGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 287.61 M. Net Loss for the year was (73.52 M) with loss before overhead, payroll, taxes, and interest of (104.76 M). | |
| ImmunoGen currently holds about 373.87 M in cash with (197.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.69. | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Hepion Pharmaceuticals faces Nasdaq delisting risk |
ImmunoGen Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ImmunoGen Stock often depends not only on the future outlook of the current and potential ImmunoGen's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ImmunoGen's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 253.6 M | |
| Cash And Short Term Investments | 275.1 M |
ImmunoGen Technical Analysis
ImmunoGen's future price can be derived by breaking down and analyzing its technical indicators over time. ImmunoGen Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ImmunoGen. In general, you should focus on analyzing ImmunoGen Stock price patterns and their correlations with different microeconomic environments and drivers.
ImmunoGen Predictive Forecast Models
ImmunoGen's time-series forecasting models is one of many ImmunoGen's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary ImmunoGen's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about ImmunoGen
Checking the ongoing alerts about ImmunoGen for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ImmunoGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| ImmunoGen is not yet fully synchronised with the market data | |
| ImmunoGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 287.61 M. Net Loss for the year was (73.52 M) with loss before overhead, payroll, taxes, and interest of (104.76 M). | |
| ImmunoGen currently holds about 373.87 M in cash with (197.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.69. | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Hepion Pharmaceuticals faces Nasdaq delisting risk |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |